SG10201914135TA - Psychotropic agents and uses thereof - Google Patents

Psychotropic agents and uses thereof

Info

Publication number
SG10201914135TA
SG10201914135TA SG10201914135TA SG10201914135TA SG10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA
Authority
SG
Singapore
Prior art keywords
amisulpride
pharmaceutical composition
serotonin
individually
dopamine
Prior art date
Application number
SG10201914135TA
Other languages
English (en)
Inventor
Andrew R Vaino
Vincent T Grattan
Zachary Prensky
Original Assignee
Lb Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lb Pharmaceuticals Inc filed Critical Lb Pharmaceuticals Inc
Publication of SG10201914135TA publication Critical patent/SG10201914135TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201914135TA 2016-11-28 2017-11-28 Psychotropic agents and uses thereof SG10201914135TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427062P 2016-11-28 2016-11-28
US201762508263P 2017-05-18 2017-05-18

Publications (1)

Publication Number Publication Date
SG10201914135TA true SG10201914135TA (en) 2020-02-27

Family

ID=62195369

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201914135TA SG10201914135TA (en) 2016-11-28 2017-11-28 Psychotropic agents and uses thereof

Country Status (11)

Country Link
US (8) US10259786B2 (ko)
EP (1) EP3544606B1 (ko)
JP (1) JP6968899B2 (ko)
KR (1) KR102274338B1 (ko)
CN (2) CN110248655B (ko)
AU (2) AU2017364899B2 (ko)
BR (1) BR112019010127A2 (ko)
ES (1) ES2908949T3 (ko)
MA (1) MA46901A (ko)
SG (1) SG10201914135TA (ko)
WO (1) WO2018098497A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377421B2 (en) * 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
WO2018213813A2 (en) * 2017-05-18 2018-11-22 Lb Pharmaceuticals Inc. Inc. Psychotropic agents and uses thereof
SG10201914135TA (en) 2016-11-28 2020-02-27 Lb Pharmaceuticals Inc Psychotropic agents and uses thereof
CN110790693A (zh) * 2018-08-02 2020-02-14 北京万全德众医药生物技术有限公司 一种(s)(-)-氨磺必利的制备方法
CA3217877A1 (en) * 2021-05-18 2022-11-24 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US4210660A (en) * 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
US4772630A (en) 1984-11-23 1988-09-20 Ciba-Geigy Corp. Benzamides and their salts
FR2678266A1 (fr) * 1991-06-28 1992-12-31 Delagrange Laboratoires Nouveaux derives de 2-hydroxy 4-amino 5-ethylsulfonyl benzamide utiles comme anxiolytiques.
AU2351895A (en) * 1994-04-28 1995-11-29 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
US5606482A (en) * 1995-04-14 1997-02-25 Lucent Technologies Inc. Solid state circuit breaker
FR2753376B1 (fr) 1996-09-18 1998-10-16 Synthelabo Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
US6169094B1 (en) 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
WO2008050341A2 (en) 2006-10-25 2008-05-02 Ramot At Tel-Aviv University Ltd Novel psychotropic agents having glutamate nmda activity
WO2012062697A1 (en) 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
US20150018360A1 (en) * 2011-09-13 2015-01-15 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders
CN102807516A (zh) * 2012-08-16 2012-12-05 四川省百草生物药业有限公司 氨磺必利的中间体及利用该中间体制备氨磺必利的方法
SG10201914135TA (en) * 2016-11-28 2020-02-27 Lb Pharmaceuticals Inc Psychotropic agents and uses thereof
WO2018213813A2 (en) 2017-05-18 2018-11-22 Lb Pharmaceuticals Inc. Inc. Psychotropic agents and uses thereof
MX2020005518A (es) 2017-12-05 2020-11-06 Sunovion Pharmaceuticals Inc Mezclas no racemicas y usos de las mismas.

Also Published As

Publication number Publication date
US20180170868A1 (en) 2018-06-21
US20240150283A1 (en) 2024-05-09
MA46901A (fr) 2019-10-02
KR20190086536A (ko) 2019-07-22
US20180155282A1 (en) 2018-06-07
AU2017364899B2 (en) 2023-07-06
US20240158347A1 (en) 2024-05-16
ES2908949T3 (es) 2022-05-04
CN111233731A (zh) 2020-06-05
EP3544606A4 (en) 2019-12-18
US20220144770A1 (en) 2022-05-12
CN110248655A (zh) 2019-09-17
WO2018098497A1 (en) 2018-05-31
US10167256B2 (en) 2019-01-01
EP3544606A1 (en) 2019-10-02
JP2019535837A (ja) 2019-12-12
JP6968899B2 (ja) 2021-11-17
US11040943B2 (en) 2021-06-22
US20200079734A1 (en) 2020-03-12
US20200055818A1 (en) 2020-02-20
EP3544606B1 (en) 2022-03-09
KR102274338B1 (ko) 2021-07-06
AU2023241329A1 (en) 2023-10-26
CN111233731B (zh) 2021-05-14
US11713295B2 (en) 2023-08-01
CN110248655B (zh) 2023-07-07
US10259786B2 (en) 2019-04-16
US10689338B2 (en) 2020-06-23
BR112019010127A2 (pt) 2019-08-20
AU2017364899A1 (en) 2019-05-30
US20200002277A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
SG10201914135TA (en) Psychotropic agents and uses thereof
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
WO2017177004A8 (en) Tertiary amides and method of use
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BRPI0706726B8 (pt) benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar
BR112016007016A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para tratamento sintomático do comprometimento cognitivo na demência, e, composição farmacêutica
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MY198113A (en) Piperidine cxcr7 receptor modulators
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
MX2017009405A (es) Compuestos de tipo ergolina y usos de estos.
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX364104B (es) Moduladores del receptor cxcr7.
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
WO2018213813A8 (en) Psychotropic agents and uses thereof
PE20160842A1 (es) Piperidiniltetrahidroquinolinas sustituidas
MX2016008898A (es) Antagonistas selectivos de nr2b.